866-997-4948(US-Canada Toll Free)

PharmaPoint: Type 2 Diabetes - France Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 222 Pages


GlobalData has released its new Country report, PharmaPoint: Type 2 Diabetes France Drug Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard onceor twice-daily therapies.

As in the global market, this growth will be fueled by the dramatic increase in the disease prevalence and diagnosis as well as by the uptake of the new branded drugs. Actos patent expiry in 2012 will not affect the French market, as the drug was withdrawn from this market in 2011. Byettas patent expiration in 2016 will not have a major impact on the market as its sales have been constantly declining, with Victoza and Bydureon overtaking its shares.

Scope

  • Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting France type 2 diabetes market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in France
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 11

2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13

3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 18
3.1.4 Quality of Life 19
3.2 Symptoms 19

4 Disease Management 21
4.1 Treatment Overview 21
4.1.1 Diagnosis and Referrals 21
4.1.2 Treatment Guidelines 22
4.2 France 28
4.2.1 Diagnosis 28
4.2.2 Clinical Practice 28

5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 30
5.3 Product Profiles - Major Brands 32
5.3.1 Metformin 32
5.3.2 Sulfonylureas (SUs) and Other Insulin Secretagogues 37
5.3.3 a-glucosidase Inhibitors (AGIs) 41
5.3.4 Thiazolidinediones (TZDs) 44
5.3.5 GLP-1 Receptor Agonists 45
5.3.6 DPP-4 Inhibitors 64
5.3.7 SGLT-2 Inhibitors 87
5.3.8 Insulin Formulations 95

6 Opportunity and Unmet Need 115
6.1 Overview 115
6.2 Unmet Needs 116
6.2.1 Drugs Providing Sustained Glycemic Control 116
6.2.2 Drugs with Non-Glycemic Benefits 117
6.2.3 Increased Patient Compliance 118
6.2.4 Drugs with Improved Side-Effect Profiles 119
6.2.5 Earlier Diagnosis 120
6.3 Unmet Needs Gap Analysis 121
6.4 Oral Therapy with Sustainable Efficacy 122
6.5 Oral Therapy Offering Weight Loss 122
6.6 Cardio-metabolic Therapy 123
6.7 Promotion of Type 2 Diabetes Drugs in Emerging Markets 123

7 Pipeline Assessment 124
7.1 Overview 124
7.2 Promising Drugs in Clinical Development 125
7.2.1 Albiglutide 130
7.2.2 Dulaglutide (LY2189265) 135
7.2.3 Semaglutide 141
7.2.4 MK-3102 145
7.2.5 Empagliflozin 149
7.2.6 Tofogliflozin 154
7.2.7 Fasiglifam (TAK-875) 157
7.2.8 LY2409021 162
7.2.9 LY2605541 (insulin peglispro) 166

8 Market Outlook 170
8.1 France 170
8.1.1 Forecast 170
8.1.2 Key Events 174
8.1.3 Drivers and Barriers 175

9 Appendix 177
9.1 Bibliography 177
9.2 Abbreviations 201
9.3 Methodology 204
9.4 Forecasting Methodology 204
9.4.1 Diagnosed Type 2 Patients 204
9.4.2 Percent Drug-Treated Patients 205
9.4.3 Drugs Included in Each Therapeutic Class 205
9.4.4 Launch and Patent Expiry Dates 206
9.4.5 General Pricing Assumptions 207

List of Table


Table 1: Symptoms of Type 2 Diabetes 20
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 21
Table 3: Treatment Guidelines for Type 2 Diabetes 23
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 26
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 31
Table 6: Product Profile - Metformin 34
Table 7: Metformin SWOT Analysis, 2012 36
Table 8: First-Generation Sulfonylureas 38
Table 9: Second-Generation Sulfonylureas 38
Table 10: Product Profile - Sulfonylureas 39
Table 11: Sulfonylureas SWOT Analysis, 2012 40
Table 12: Product Profile - Acarbose 42
Table 13: AGIs SWOT Analysis, 2012 44
Table 14: GLP-1 Receptor Agonists 47
Table 15: Product Profile - Byetta 49
Table 16: Byetta SWOT Analysis, 2012 51
Table 17: Product Profile - Victoza 53
Table 18: Victoza SWOT Analysis, 2012 55
Table 19: Product Profile - Bydureon 57
Table 20: Bydureon SWOT Analysis, 2012 59
Table 21: Product Profile - Lyxumia 61
Table 22: Lyxumia SWOT Analysis, 2012 64
Table 23: Marketed DPP-4 Inhibitors 66
Table 24: Marketed DPP-4 Inhibitors in Combination with Other OADs 66
Table 25: Product Profile - Januvia 68
Table 26: Januvia SWOT Analysis, 2012 70
Table 27: Product Profile - Onglyza 72
Table 28: Onglyza SWOT Analysis, 2012 74
Table 29: Product Profile - Tradjenta 76
Table 30: Tradjenta SWOT Analysis, 2012 78
Table 31: Product Profile - Galvus 80
Table 32: Galvus SWOT Analysis, 2012 83
Table 33: Product Profile - Nesina 84
Table 34: Nesina SWOT Analysis, 2012 86
Table 35: Product Profile - Forxiga 89
Table 36: Forxiga SWOT Analysis, 2012 91
Table 37: Product Profile - Invokana 92
Table 38: Invokana SWOT Analysis, 2012 94
Table 39: Insulins - Overview and Comparison 96
Table 40: Insulin Formulations 96
Table 41: Product Profile - Humalog 97
Table 42: Humalog SWOT Analysis, 2012 99
Table 43: Product Profile - Lantus 100
Table 44: Lantus SWOT Analysis, 2012 103
Table 45: Product Profile - Levemir 104
Table 46: Levemir SWOT Analysis, 2012 106
Table 47: Product Profile - Novolog 107
Table 48: Novolog SWOT Analysis, 2012 108
Table 49: Product Profile - Apidra 109
Table 50: Apidra SWOT Analysis, 2012 111
Table 51: Product Profile - Tresiba 112
Table 52: Tresiba SWOT Analysis, 2012 114
Table 53: Overall Unmet Needs - Current Level of Attainment 115
Table 54: Clinical Unmet Needs - Gap Analysis, 2013 121
Table 55: Type 2 Diabetes - Phase Pipeline, 2012 127
Table 56: Comparison of Therapeutic Classes in Development for Type 2 Diabetes, 2012 128
Table 57: Product Profile - Albiglutide 131
Table 58: Albiglutide SWOT Analysis, 2013 135
Table 59: Product Profile - Dulaglutide 137
Table 60: Dulaglutide SWOT Analysis, 2012 141
Table 61: Product Profile - Semaglutide 142
Table 62: Semaglutide SWOT Analysis, 2012 145
Table 63: Product Profile - MK-3102 146
Table 64: MK-3102 SWOT Analysis, 2013 148
Table 65: Product Profile - Empagliflozin 150
Table 66: Empagliflozin SWOT Analysis, 2013 153
Table 67: Product Profile - Tofogliflozin 155
Table 68: Tofogliflozin SWOT Analysis, 2013 157
Table 69: Product Profile - Fasiglifam 158
Table 70: Fasiglifam SWOT Analysis, 2013 161
Table 71: Product Profile - LY2409021 163
Table 72: LY2409021 SWOT Analysis, 2013 165
Table 73: Product Profile - LY2605541 167
Table 74: LY2605541 SWOT Analysis, 2013 169
Table 75: France Sales Forecasts ($m) for Type 2 Diabetes, 2012-2022 171
Table 76: Key Events Impacting Sales for Type 2 Diabetes in France, 2012-2022 174
Table 77: Type 2 Diabetes Market - Drivers and Barriers in France, 2012 175
Table 78: Key Launch Dates 206
Table 79: Key Patent Expiries 206
Table 80: Number of High-Prescribing Physicians Surveyed 218

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 25
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Type 2 Diabetes, 2012-2022 129
Figure 3: Sales for Type 2 Diabetes in France by Drug Class, 2012-2022 173

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *